Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo Benefits From McNeil Recall, Prepares Infant Formula Launches

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson's extensive recall of leading brand name analgesics spurred sales growth for Perrigo's private-label products in the category during the firm's most recent earnings period

Related Content

Perrigo's Generic Mucinex Becomes A Long Shot To Launch In Fiscal 2011
Reckitt Would Add Durex, Scholl Brands With SSL Acquisition
Perrigo Gains Pole Position In Private-Label Allegra Race
Perrigo Targets October For Quality System Corrections, FDA Re-Inspection
NBTY Expects Potholes On Private Label Profit Road
Recall Stifles J&J's Consumer Product Sales Growth
Recall Stifles J&J's Consumer Product Sales Growth
Perrigo Grows Into Adjacent Infant Formula Category With PBM Acquisition
Reckitt's Lysol Innovation Leads Launches As Acquisition Talk Subsides
Perrigo Licenses Antihistamine Levocetirizine, “Prime” Switch Candidate





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts